Every acquisition appears unique. A different disease. A different company. A different price tag.

Yet beneath the surface, many of today's pharmaceutical deals are driven by the same force. Not optimism. Not certainty. But urgency.

Increasingly, Big Pharma no longer fears buying the wrong company as much as it fears watching a competitor buy the right one.

Developing a new medicine is a marathon. It can take more than a decade of research, clinical trials and regulatory scrutiny before a single patient receives treatment. If successful, that medicine can transform a company - generating billions of dollars in annual revenue, funding the next generation of research, supporting thousands of jobs and, most importantly, improving the lives of millions of patients.

Then, one morning, the patent expires.

Almost overnight, generic or biosimilar competitors enter the market, eroding prices and stripping away billions of dollars in revenue. A product that once underpinned an entire business can rapidly become a fraction of its former value.

For years, large pharmaceutical companies could afford to be patient. They would monitor promising biotechnology firms, wait for late-stage clinical data to reduce scientific uncertainty, and only then decide whether an acquisition was justified.

That strategy is becoming increasingly difficult to sustain.

Competition for high-quality assets has intensified dramatically. Companies are acquiring earlier and accepting greater scientific risk, not because the science has become more predictable, but because waiting has become more dangerous.

At first glance, this surge in dealmaking appears to reflect confidence in biotechnology's future.

In reality, it may reveal something else entirely.

The fear of missing out.

The Clock Is Ticking

For decades, the pharmaceutical industry operated on a relatively predictable rhythm. Companies discovered medicines, enjoyed years of market exclusivity under patent protection, and used the resulting revenues to fund the next generation of innovation. Acquisitions certainly played a role, but they were often opportunistic rather than essential.

Now that rhythm is breaking down. Over the next decade, many of the industry's highest-grossing medicines will lose patent protection. Drugs that have generated tens of billions of dollars annually - including treatments for cancer, autoimmune disease and cardiovascular conditions - are approaching what the industry refers to as the 'patent cliff'.

Patent cliff: The steep drop in a drug's sales once its patent protection expires and cheaper generic or biosimilar copies are free to enter the market - often erasing the majority of a product's revenue within a few years.

Blockbuster medicines often fund entire research portfolios, shareholder returns and future acquisitions. Replacing one successful therapy is difficult enough; replacing several simultaneously presents an enormous strategic challenge.

Over $300 billion in prescription drug revenue is expected to lose exclusivity between 2025 and 2030.1 Eliquis (apixaban), the anticoagulant co-commercialised by Bristol Myers Squibb and Pfizer, is among the largest of those events: it lost European exclusivity in May 2026, and generic manufacturers that settled their patent litigation may launch in the United States from 1st April 2028.2 Keytruda (pembrolizumab), the flagship oncology medicine of Merck & Co., generated $31.7 billion in 2025 and faces loss of exclusivity in the United States from 2028, though European protection runs to 2031.3

A note on names: Two entirely separate companies trade under the Merck name. This article refers throughout to Merck & Co., the American group headquartered in Rahway, New Jersey and listed on the NYSE as MRK, which operates as MSD everywhere outside the United States and Canada. It is not Merck KGaA of Darmstadt, the German group that holds the Merck trademark in the rest of the world and trades as EMD in North America. The two have been separate since 1917.

Key figures: Prescription drug revenue losing exclusivity, 2025-2030: over $300bn · Keytruda 2025 sales: $31.7bn (US exclusivity to 2028, EU to 2031) · Eliquis: European exclusivity lost May 2026, settled US generic entry from April 2028 · Biopharma M&A deals in H1 2026: 52, up from around 30 in H1 2025

The pressure is not limited to one or two companies - it is systemic.

The result is a race against time.

Every year that passes without securing the next generation of therapies shortens the window available to replace declining revenues. In this environment, waiting for perfect clinical evidence can become more costly than acting on imperfect information.

The question facing pharmaceutical executives is no longer simply:

'Is this science good enough?''

It is increasingly:

'Can we afford for someone else to own it instead?'

Keytruda worldwide sales ($bn), 2018-2025. Source: Merck & Co. annual results.

That performance makes Keytruda one of the largest pharmaceutical products ever launched. With its core patents facing expiry from 2028 onwards, it is also the starkest illustration of the revenue Merck & Co. must now find a way to replace.

Why Did Waiting Become Expensive?

Big Pharma once had the luxury of waiting for clinical data before pursuing acquisitions. Today, promising assets attract multiple suitors, turning successful trial results into competitive auctions. In many cases, waiting for certainty means paying significantly more - or losing the asset altogether.

The numbers reflect this shift. BioSpace recorded 52 biopharma mergers and acquisitions in the first half of 2026, compared with around 30 during the same period in 2025 - an increase of more than 70 per cent.4

One notable example is Merck & Co.'s $6.7 billion acquisition of Terns Pharmaceuticals, announced in March 2026 and valuing the biotech at $5.7 billion net of its cash. The deal gave Merck & Co. access to TERN-701, an oral treatment for chronic myeloid leukaemia (CML) then still in phase 1/2 trials. It illustrates how pharmaceutical companies are increasingly willing to pay for promising assets well before they reach the market, helping to build the next generation of blockbuster medicines as products like Keytruda approach patent expiry.5

The logic is not that the science has become more predictable. It is that the risk has changed shape. Pharmaceutical companies are no longer weighing scientific risk alone; they are weighing competitive risk alongside it. Waiting for more clinical data reduces the first and increases the second, and the second has become the more expensive of the two.

How China Has Changed the Equation

Competition for new therapeutics is no longer confined to the US and Europe. Over the past decade, China has emerged as one of the world's fastest-growing biotechnology hubs, producing an increasing number of innovative therapies that are attracting global pharmaceutical companies.

Several factors have driven this shift, including faster patient recruitment due to a large patient population, lower clinical trial costs and a rapidly expanding biotech ecosystem. As a result, licensing deals with Chinese biotech firms have become an increasingly important source of innovation for Big Pharma.

Investors have taken notice. In July 2026, as emerging-market technology stocks fell into a bear market, healthcare became the best-performing sector in Bloomberg's emerging-market benchmark, with at least ten Chinese pharmaceutical stocks posting double-digit gains.6

The search for the next set of blockbuster medicines is now truly global, with pharmaceutical companies racing to secure promising assets wherever they emerge.

The Cost of Being Wrong

None of this makes the strategy safe. Buying early means buying before the science is settled, and most medicines that enter clinical trials never reach patients. There is no guarantee that any given acquisition will succeed.

But for many of the world's largest drugmakers, the cost of missing the next breakthrough may now outweigh the cost of backing the wrong one.

Final Thoughts

Behind every billion-dollar acquisition is a patient waiting.

Waiting for a treatment that could change their life.

Waiting for another option when every existing therapy has failed.

Waiting for a scientific breakthrough to make the journey from laboratory to hospital.

The race for the next blockbuster medicine is not just a battle between companies.

It is a race against time.

Because while companies can recover lost deals, patients can never recover lost time.

Footnotes

  1. Evaluate, Portfolio Tactics to Scale the $300bn Patent Cliff (opens in a new tab), 13th October 2025PharmaVoice, Big Pharma navigating the $300 billion patent cliff (opens in a new tab), 30th January 2026. ↩

  2. Pfizer Inc., Annual Report on Form 10-K for the financial year ended 31st December 2025 (opens in a new tab). ↩

  3. Merck & Co., Inc., Annual Report on Form 10-K for the financial year ended 31st December 2025 (opens in a new tab), filed 24th February 2026. ↩

  4. BioSpace, Biopharma strikes 50+ M&A deals in H1, led by Lilly's $25B spend (opens in a new tab), 1st July 2026. ↩

  5. Fierce Biotech, Merck flies toward promising CML asset with $6.7B Terns acquisition (opens in a new tab), 25th March 2026. ↩

  6. Bloomberg, Chinese Biotech Overtakes AI as Emerging-Market Growth Trade (opens in a new tab), 27th July 2026. ↩